- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05873296
Health Education for Women With Breast Cancer
December 3, 2025 updated by: Andréa Dias Reis, Federal University of Maranhao
Impact of Health Education on Lifestyle for Women With Breast Cancer: Health Education
The sedentary lifestyle in women with breast cancer generates a problem for public health.
An alternative that has been used to reduce sedentary behavior are interventions with the use of information technology, as well as projects with health education can cause lifestyle changes.
However, little is known about the effect of these interventions on self-awareness and self-care in women with breast cancer.
This aim of study is evaluate the effect of health education on sedentary behavior, lifestyle, physical activity level, nutrition, self-esteem, anxiety and depression, quality of life, pain, functional capacity, and strength in women with breast cancer.
This is a study the 12 weeks, with patients being treated for breast cancer, distributed for two groups: Group Health Education Recommendations and Control Group.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a clinical trial with patients being treated for breast cancer, the sample will be randomly distributed into two groups: Group Health Education Recommendations (GRES) and Control Group (CG), which will remain in usual care.
The intervention will last for 12 weeks, where GRES will receive health education recommendations in person and via social media.
The endpoints of this study are sedentary behavior, lifestyle, physical activity level, nutrition, self-esteem, anxiety and depression, quality of life, pain, functional capacity, and strength.
Evaluations will be performed at baseline, after 6 weeks, and after 12 weeks.
Data will be analyzed by multivariate, comparing the effects of group, time, and interaction in SPSS software version 24.0, with α=5%.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maranhão
-
São Luís, Maranhão, Brazil, 65058185
- Andréa Dias Reis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Women 18 years or older;
- Diagnosed with breast cancer;
- Ongoing breast cancer treatment (chemotherapy, radiotherapy and/or hormone therapy);
- Have daily access to a smartphone.
Exclusion Criteria:
- Women having another type of cancer;
- Perform physical training for three months before the intervention;
- Has medical contraindication to perform any type of physical activity;
- Have filled in yes on the PAR-Q and medical contraindication;
- Without cognitive conditions to use a smartphone or answer questionnaires;
- Illiterate women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Health Education
Group of women being treated for breast cancer
|
The intervention will last for 12 weeks, a health education program (face-to-face meetings and information in social networks).
|
|
No Intervention: usual care
Group of women who will remain in usual care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Life habits
Time Frame: Change from baseline, 6 weeks Life habits at 12 weeks
|
Lifestyle will be evaluated by Individual Lifestyle Profile Questionnaire (score 0 to 3 - higher score is better)
|
Change from baseline, 6 weeks Life habits at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body composition (lean mass, fat mass)
Time Frame: Change from baseline, 6 weeks Body composition at 12 weeks
|
Body Composition will be evaluated by Sanny Tetrapolar Bioimpedance (Model 1011)
|
Change from baseline, 6 weeks Body composition at 12 weeks
|
|
Sitting time
Time Frame: Change from baseline, 6 weeks Sitting time at 12 weeks
|
Sedentary behavior will be evaluated by triaxial accelerometers motion sensor Actigraph GT3X model
|
Change from baseline, 6 weeks Sitting time at 12 weeks
|
|
Time and level the physical activity
Time Frame: Change from baseline, 6 weeks Time and level the physical activity at 12 weeks
|
Physical activity level will be evaluated by triaxial accelerometers motion sensor Actigraph, GT3X model.
|
Change from baseline, 6 weeks Time and level the physical activity at 12 weeks
|
|
Level the self-esteem
Time Frame: Change from baseline, 6 weeks Level the self-esteem at 12 weeks
|
Self-esteem will be evaluated by Rosenberg Self-Esteem Scale (score 1 to 4 - higher score is better and worse outcome, depends on the question)
|
Change from baseline, 6 weeks Level the self-esteem at 12 weeks
|
|
Dimensions the quality of Life from cancer
Time Frame: Change from baseline, 6 weeks Dimensions the quality of Life at 12 weeks
|
Quality of Life will be evaluated by European Organization for Research and Treatment of Cancer Quality of Life Questionnarie - 30 questions (score 1 to 4 - higher score is worse outcome)
|
Change from baseline, 6 weeks Dimensions the quality of Life at 12 weeks
|
|
Dimensions the quality of Life from breast cancer
Time Frame: Change from baseline, 6 weeks Dimensions the quality of Life at 12 weeks
|
Quality of Life will be evaluated by European Organization for Research and Treatment of Cancer Quality of Life Questionnarie - 23 questions (score 1 to 4 - higher score is worse outcome)
|
Change from baseline, 6 weeks Dimensions the quality of Life at 12 weeks
|
|
Level the pain
Time Frame: Change from baseline, 6 weeks Level the pain at 12 weeks
|
Pain will be evaluated by Brief Pain Inventory (score 1 to 10 - higher score is worse outcome)
|
Change from baseline, 6 weeks Level the pain at 12 weeks
|
|
Eating habits
Time Frame: Change from baseline, 6 weeks Eating habits at 12 weeks
|
Eating behavior will be evaluated by (score 1 to 4 - higher score is better outcome)
|
Change from baseline, 6 weeks Eating habits at 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Andréa D Reis, Federal University of Maranhao
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Fridriksdottir N, Gunnarsdottir S, Zoega S, Ingadottir B, Hafsteinsdottir EJG. Effects of web-based interventions on cancer patients' symptoms: review of randomized trials. Support Care Cancer. 2018 Feb;26(2):337-351. doi: 10.1007/s00520-017-3882-6. Epub 2017 Sep 18.
- Ghosn B, Benisi-Kohansal S, Ebrahimpour-Koujan S, Azadbakht L, Esmaillzadeh A. Association between healthy lifestyle score and breast cancer. Nutr J. 2020 Jan 14;19(1):4. doi: 10.1186/s12937-020-0520-9.
- Gao Z, Ryu S, Chen Y. Effects of Tai Chi App and Facebook health education programs on breast cancer survivors' stress and quality of life in the Era of pandemic. Complement Ther Clin Pract. 2022 Aug;48:101621. doi: 10.1016/j.ctcp.2022.101621. Epub 2022 Jun 16.
- Hardcastle SJ, Maxwell-Smith C, Kamarova S, Lamb S, Millar L, Cohen PA. Factors influencing non-participation in an exercise program and attitudes towards physical activity amongst cancer survivors. Support Care Cancer. 2018 Apr;26(4):1289-1295. doi: 10.1007/s00520-017-3952-9. Epub 2017 Oct 31.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2023
Primary Completion (Actual)
November 30, 2024
Study Completion (Actual)
December 30, 2024
Study Registration Dates
First Submitted
March 22, 2023
First Submitted That Met QC Criteria
May 15, 2023
First Posted (Actual)
May 24, 2023
Study Record Updates
Last Update Posted (Actual)
December 10, 2025
Last Update Submitted That Met QC Criteria
December 3, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Skin Diseases
- Breast Diseases
- Behavior
- Skin and Connective Tissue Diseases
- Treatment Adherence and Compliance
- Health Behavior
- Patient Compliance
- Patient Acceptance of Health Care
- Adherence Interventions
- Medication Adherence
- Breast Neoplasms
- Sedentary Behavior
- Health Education
Other Study ID Numbers
- UFMA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
University of Kansas Medical CenterRecruitingBreast Cancer FemaleUnited States
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Dalarna County Council, SwedenRecruitingBreast Cancer - FemaleSweden
-
Al-Quds UniversityNot yet recruitingThe Effect of Psychosocial Support on Improving Breast Cancer Patients Response to Medical TreatmentBreast Cancer - FemalePalestinian Territories
-
Izmir Biomedicine and Genome CenterDokuz Eylul University; Antalya Training and Research Hospital; Akdeniz University...Enrolling by invitationFemale Breast Cancer PatientsTurkey (Türkiye)
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
Clinical Trials on Health Education
-
Federal University of PelotasActive, not recruiting
-
University of PretoriaUnknown
-
Ankara UniversityCompletedEducation | Fertility | YouthTurkey
-
Universiti Sains MalaysiaNot yet recruitingKnowledge, Attitudes, Practice | Early Childhood Caries
-
Junyan ZhaoActive, not recruitingTumor Chemotherapy PatientsChina
-
Tianjin HospitalCompletedLumbar Disc HerniationChina
-
Cardenal Herrera UniversityRecruiting
-
Saglik Bilimleri Universitesi Gulhane Tip FakultesiCompletedMotivational Interviewing | Health EducationTurkey (Türkiye)
-
Zhongnan HospitalRecruitingLymphoma | Leukaemia | Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaChina
-
T.C. ORDU ÜNİVERSİTESİNot yet recruitingHealth Education | Cervical Cancers | Peer Support